DECISIVE

Dutch consortium preparing a growth fund application



What?

Dutch Medical Isotopes Save Lives (DECISIVE) is a consortium in NL preparing a National Growth Fund (NGF) application to strengthening the entire chain of the nuclear medicine field to be ready for the future developments and market. Application is foreseen for round 4, deadline Q3 2024. NGF is an initiative from Dutch Ministry of Economic Affairs to boost NL economy.

How?

Collaboration of industry, academy, society and government (quadruple helix). Acquire funding for:

- Infrastructure for the development and evaluation of new radiopharmaceuticals: research & innovation, product development, regulation, translational (molecule to patient).
- Production facilities for radionuclides: availability, sustainability, independence from outside factors.
- National education (MBO/HBO/BSc/MSc): more and better trained personnel.
- Central image analysis center harmonization, standardization, dosimetry, AI.

Why?

An important momentum has been created in the social, economic and academic field to allow NL to continue to grow as a leading country in nuclear medicine:

- The worldwide market will increase 3 times in the coming 10 years.
- NL is a market leader in provision of sustainable radionuclide availability and will be in the future through building the high-flux PALLAS reactor.
- Dutch innovation and industry is strong.
- Nearly the full pipeline exists in NL.

Who?

- The starting idea of DECISIVE originates from a consortium of Erasmus MC, Radboudumc, UMCG and FAST.
- We want to include all Dutch academic institutes, national industry & international.
 value-added industry and governmental & social organizations such as patient associations.
- Ministry of Health (VWS) supports DECISIVE via program directorate Medical Isotopes.
- Catalyze selected as consultant & co-writers.

